CSCI (Aeterna Zentaris) Market Value to Book Value Ratio

Aeterna Zentaris (CSCI) - corporate logo

The ratio of the company's market value to its book assets on the GURU.Markets terminal chart demonstrates the pricing flexibility of COSCIENS Biopharma Inc. (CSCI) due to its narrow set of diagnostic tests. Meanwhile, the 1.64 indicator points to the status of an asset whose development is based on external production and outsourced testing. The use of long-term patents in endocrinology creates sustainable demand, guaranteeing the business high margins for years.

Market Capitalization to Net Assets: COSCIENS Bio (CSCI) for 08/10/2024 - 09/14/2025

CSCI (COSCIENS Biopharma Inc): analytical breakdowns and indicator data

- price and consensus price forecast:
Stock Price COSCIENS Biopharma Inc.|CSCI - Analyst Median Target
- market capitalization data:
Market Value Aeterna Zentaris|CSCI - Company Buyout Price
- book capitalization data:
Net Assets per Single Share COSCIENS Biopharma|CSCI - Net Asset Value|Market Capitalization to Book Value Ratio cosciensbio.com|CSCI - Company Assets
- debt and liquidity data:
Total Debt to Capital COSCIENS Biopharma Inc.|CSCI - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Aeterna Zentaris|CSCI - Company Total Debt Obligations|Debts to Book Capitalization Aeterna Zentaris
Initial company analysis:COSCIENS Biopharma Inc. - CSCI
Finished products of COSCIENS Biopharma Inc

COSCIENS Biopharma Inc. (CSCI) operates in a preclinical development phase with no current sales. Under these conditions, the indicator becomes extremely sensitive to changes in net assets and market expectations. This metric compares the current market value of the business to its book value, measuring the premium the market is willing to pay for the future success of its drug pipeline. By analyzing changes in the market capitalization-to-book value multiple, investors can assess the risk of asset overvaluation.

Direct competitors

Vertex Pharmaceuticals - Market Capitalization to Book Value Ratio|ALNY (alnylam.com) - Market Capitalization to Book Value|INSM: Market Value to Book Value Ratio|Market Capitalization to Book Value UTHR|BMRN - Market Value to Book Value Ratio|Market Capitalization to Net Assets BridgeBio Corp (BBIO)|BGM: Market Capitalization to Book Value Ratio|Market-to-Book Ratio cogentbio.com COGT|XERS: Market Capitalization to Book Value Ratio|KROS - Market Cap to Net Assets Ratio|Arcturus Pharma - Market Capitalization to Book Value Ratio|Eton Corp (ETON) - Market Capitalization to Book Value|KMDA (Kamada Ltd.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio FULC|Market Value to Book Value Ratio Abeona Therapeutics (ABEO)|Market Value to Book Value Ratio mereobiopharma.com (MREO)|Market Capitalization to Book Value Ratio PLX|PLRX - Market Capitalization to Book Value|Market Cap to Net Assets Ratio Applied Therapeutics|RNTX - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio GELS|Aytu BioPharma (AYTU) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio Chemomab Therapeutics Ltd (CMMB)|Capitalization to Book Value Ratio SRx Health (SRXH)|Polyrizon Ltd (PLRZ) - Market Cap to Net Assets Ratio|Market Value to Book Value AEZS (zentaris.com)|Cyclo Therapeutics, Inc. (CYTH) - Market Value to Book Value Ratio|Market Capitalization to Net Assets Inozyme Pharma Inc. INZY|Market Capitalization to Book Value Ratio Reneo Pharma (RPHM)